Clopidogrel may cause gingival bleeding, and in addition to gingival bleeding may cause bleeding from the gastrointestinal tract, skin mucosa, or intracranial hemorrhage. The main indication for clopidogrel is the prevention of atherosclerotic thrombosis, which is more suitable for patients with myocardial infarction, patients with recent ischemic stroke, and patients with peripheral arterial disease. According to the relevant product specification, clopidogrel is a platelet aggregation inhibitor, which can inhibit platelet aggregation to prevent the formation of atherosclerotic thrombosis. However, platelets are a key factor in hemostasis, and when platelets fail to aggregate, the corresponding risk of bleeding will increase. Therefore, clopidogrel has the side effect of inducing bleeding, including gastrointestinal bleeding, skin and mucous membrane bleeding, gum bleeding and so on. In addition, clopidogrel has clear contraindications, it is not suitable for patients who are allergic to the active substance or any of the components of clopidogrel, severe hepatic impairment, and the presence of active pathologic bleeding (such as peptic ulcers or intracranial bleeding).